2022. Plasma exosome-derived fragile site-associated tumor suppressor as a powerful prognostic predictor for patients with ovarian cancer. Biomolecules and Biomedicine. 22, 3 (Jun. 2022), 453–459. DOI:https://doi.org/10.17305/bjbms.2021.6404.